Novel Development of Nanoparticles-A Promising Direction for Precise Tumor Management

• Published in: Pharmaceutics Vol. 15; no. 1; p. 24
• Main Authors: Zhang, Dengke, Tang, Qingqing, Chen, Juan, Wei, Yanghui, Chen, Jiawei
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21.12.2022; MDPI
• Subjects: Antigens; antitumor drug; Biocompatibility; Bone cancer; Breast cancer; Cancer therapies; Chemotherapy; Epidermal growth factor; Experiments; Fibroblasts; Gene therapy; Kinases; Ligands; Metastasis; Monoclonal antibodies; Nanoparticles; Permeability; Prostate; Proteins; Radiation therapy; Review; tumor-targeting; Tumors; Vascular endothelial growth factor; Vitamin B; antitumor drug; tumor-targeting; nanoparticles
• ISSN: 1999-4923; 1999-4923
• DOI: 10.3390/pharmaceutics15010024

Although the clinical application of nanoparticles is still limited by biological barriers and distribution, with the deepening of our understanding of nanoparticles over the past decades, people are gradually breaking through the previous limitations in the diagnosis and treatment of tumors, providing novel strategies for clinical decision makers. The transition of nanoparticles from passive targeting to active tumor-targeting by abundant surface-modified nanoparticles is also a development process of precision cancer treatment. Different particles can be used as targeted delivery tools of antitumor drugs. The mechanism of gold nanoparticles inducing apoptosis and cycle arrest of tumor cells has been discovered. Moreover, the unique photothermal effect of gold nanoparticles may be widely used in tumor therapy in the future, with less side effects on surrounding tissues. Lipid-based nanoparticles are expected to overcome the blood-brain barrier due to their special characteristics, while polymer-based nanoparticles show better biocompatibility and lower toxicity. In this paper, we discuss the development of nanoparticles in tumor therapy and the challenges that need to be addressed.